Achieve Life Sciences, Inc. (ACHV) Cash Flow Statement

The OCF/NI ratio of 0.14 in 2026Q2 underscores the gap between reported losses and actual cash burn, with the difference largely attributable to non-cash stock-based compensation and possibly warrant revaluation. Excluding these non-cash items, the underlying cash burn appears more moderate, around $18M per quarter, which is more consistent with prior quarters. This suggests that headline net losses overstate the immediate cash consumption, but the trend of increasing cash outflows remains concerning.

The quarterly FCF deficit has roughly doubled over the past two years, reflecting increased R&D and SG&A spending as the company prepares for NDA resubmission and commercial launch. The absence of revenue means FCF margins are undefined, but the widening gap between cash burn and any potential future revenue highlights the urgency of securing additional funding. Investors should monitor whether the pace of burn stabilizes or accelerates further as CMC activities and commercial build-out continue.

The near-zero capital expenditures suggest that ACHV's business model relies on outsourced manufacturing and contract research, rather than owning hard assets. However, the recent transition of drug product manufacturing to the U.S. may necessitate future CapEx for facility setup or equipment, which could increase capital intensity. For now, the lack of CapEx means that all cash burn is operational, making the company's runway entirely dependent on operating cash flows and external financing.

The volatility in working capital is likely tied to the timing of clinical trial site payments and accruals, which can cause lumpy cash flows. The negative working capital change in 2026Q2 suggests a build-up of receivables or a reduction in payables, possibly related to increased CMC activities. These swings are not indicative of operational efficiency but rather the irregular nature of pre-revenue biotech operations, and they can obscure the underlying burn rate.

With no revenue and a negative cash balance trajectory, capital deployment is solely focused on funding clinical and regulatory activities. The absence of buybacks or dividends is expected for a clinical-stage biotech, but the company's history of dilutive equity raises suggests that future financing will likely come from share issuance. Given the current cash position of $20.9M and an average quarterly burn of around $10M, the company may need to raise capital within the next two quarters, which could further dilute existing shareholders.

The significant gap between cumulative net income and operating cash flow is primarily due to non-cash charges such as stock-based compensation and possibly warrant revaluations. This divergence indicates that the economic cost of operations is lower than accounting losses suggest, but it also means that the company's cash needs are less severe than headline numbers imply. However, the cumulative cash burn of nearly $100M underscores the substantial funding required to reach commercialization, and the recent CRL delay extends this period, increasing the risk of further dilution.